Primary cutaneous B-cell lymphoma: treatment with low dose intralesional recombinant interferon-alpha 2A.
Rubegni
P
P
De Aloe
G
G
Pianigiani
E
E
Lazzi
S
S
Fimiani
M
M
D015703:Antigens, CD / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007150:Immunohistochemistry; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012867:Skin / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*
D015703:Antigens, CD; D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins